This article has been cited by
1SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway
Benjiang Qian,Yi Yao,Changming Liu,Jiabing Zhang,Huihong Chen,Huizhang Li
International Journal of Oncology.2017;50(5)1601
[DOI]
2Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways
Guanzhao Liang,Musang Liu,Qiong Wang,Yongnian Shen,Huan Mei,Dongmei Li,Weida Liu
Oncotarget.2017;8(17)28510
[DOI]
3The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer
L S D'Abronzo,S Bose,M E Crapuchettes,R E Beggs,R L Vinall,C G Tepper,S Siddiqui,M Mudryj,F U Melgoza,B P Durbin-Johnson,R W deVere White,P M Ghosh
Oncogene.2017;36(46)6359
[DOI]
4Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
Brandon Bumbaca,Wei Li
Acta Pharmaceutica Sinica B.2018;8(4)518
[DOI]
5Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer
Cuicui Zhu,Qingyi Zhu,Zhaomeng Wu,Yingying Yin,Dan Kang,Shan Lu,Ping Liu
Journal of Cellular Physiology.2018;233(2)1104
[DOI]
6Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer
Chenchu Lin,Travis C. Salzillo,David A. Bader,Sandi R. Wilkenfeld,Dominik Awad,Thomas L. Pulliam,Prasanta Dutta,Shivanand Pudakalakatti,Mark Titus,Sean E. McGuire,Pratip K. Bhattacharya,Daniel E. Frigo
Journal of Cellular Physiology.2019;1210(2)185
[DOI]
7Derivatives containing both coumarin and benzimidazole potently induce caspase-dependent apoptosis of cancer cells through inhibition of PI3K-AKT-mTOR signaling
Haitao Liu,Yubin Wang,Ashok Sharma,Rui Mao,Na Jiang,Boying Dun,Jin-Xiong She
Anti-Cancer Drugs.2015;1210(2)1
[DOI]
8Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
Sirin Saranyutanon,Sanjeev Kumar Srivastava,Sachin Pai,Seema Singh,Ajay Pratap Singh
Cancers.2019;12(1)51
[DOI]
9miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A
Xiaodi Qiu,Ying Dou
Biomedicine & Pharmacotherapy.2017;88(1)430
[DOI]
10ING5 inhibits cancer aggressiveness by inhibiting Akt and activating p53 in prostate cancer
Neslisah Barlak,Ozel Capik,Fatma Sanli,Ahsen Kilic,Abdulmelik Aytatli,Aysenur Yazici,Serkan Ortucu,Michael Ittmann,Omer Faruk Karatas
Cell Biology International.2020;44(1)242
[DOI]
11Investigational serine/threonine kinase inhibitors against prostate cancer metastases
Claudio Festuccia
Expert Opinion on Investigational Drugs.2017;26(1)25
[DOI]
12An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
Jianqing Lin,Aileen Deng,Jean Hoffman-Censits,Geoffrey Gibney,Terry Hyslop,Brooke Miller,Deborah Kilpatrick,Serge Jabbour,William Kevin Kelly
Cancer Treatment Communications.2015;4(1)192
[DOI]
13Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth
Meng Zhang,Yin Sun,Jialin Meng,Li Zhang,Chaozhao Liang,Chawnshang Chang
Cancer Letters.2019;442(1)483
[DOI]
14A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers
Philipp Y Maximov,Balkees Abderrahman,Ramona F Curpan,Yousef M Hawsawi,Ping Fan,V Craig Jordan
Endocrine-Related Cancer.2018;25(2)R83
[DOI]
15NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer
Zhixiong Chen,Qilong Jiang,Pingyu Zhu,Yanlin Chen,Xuemei Xie,Zhongbo Du,Li Jiang,Wei Tang
The Prostate.2019;79(1)44
[DOI]
16Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes
Matthew Utter,Sohag Chakraborty,Limor Goren,Lucas Feuser,Yuan-Shan Zhu,David A. Foster
Cancer Letters.2018;423(1)28
[DOI]
17The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells
C Morell,A Bort,D Vara,A Ramos-Torres,N Rodríguez-Henche,I Díaz-Laviada
Prostate Cancer and Prostatic Diseases.2016;19(3)248
[DOI]
18Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas
Tomotaka Shimura,Yuichiro Tada,Hideaki Hirai,Daisuke Kawakita,Satoshi Kano,Kiyoaki Tsukahara,Akira Shimizu,Soichiro Takase,Yorihisa Imanishi,Hiroyuki Ozawa,Kenji Okami,Yuichiro Sato,Yukiko Sato,Chihiro Fushimi,Hideaki Takahashi,Takuro Okada,Hiroki Sato,Kuninori Otsuka,Yoshihiro Watanabe,Akihiro Sakai,Koji Ebisumoto,Takafumi Togashi,Yushi Ueki,Hisayuki Ota,Mizuo Ando,Shinji Kohsaka,Toyoyuki Hanazawa,Hideaki Chazono,Yoshiyuki Kadokura,Hitome Kobayashi,Toshitaka Nagao
Oncotarget.2018;9(2)1852
[DOI]
19Persistent androgen receptor addiction in castration-resistant prostate cancer
Michael T. Schweizer,Evan Y. Yu
Journal of Hematology & Oncology.2015;8(1)1852
[DOI]
20Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors
Yang Liu,Yanzhen Yin,Jingya Zhang,Krystle Nomie,Liang Zhang,Dezhi Yang,Michael L. Wang,Guisen Zhao
Archiv der Pharmazie.2016;349(5)356
[DOI]
21Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy
Xuechao Wan,Honglei Pu,Wenhua Huang,Shu Yang,Yalong Zhang,Zhe Kong,Zhuoran Yang,Peiqing Zhao,Ao Li,Tao Li,Yao Li
Oncotarget.2016;7(32)51284
[DOI]
22Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer
Giorgio Ivan Russo,Jörg Hennenlotter,Ulrich Vogel,Ursula Kühs,Thomas Manfred Wurm,Valentina Gerber,Tim Neumann,Sebastiano Cimino,Arnulf Stenzl,Tilman Todenhöfer
Disease Markers.2019;2019(32)1
[DOI]
23HOXA1 enhances the cell proliferation, invasion and metastasis of prostate cancer cells
HAITAO WANG,GUANZHONG LIU,DAN SHEN,HUAMAO YE,JINMING HUANG,LI JIAO,YINGHAO SUN
Oncology Reports.2015;34(3)1203
[DOI]
24Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Pier-Luc Clermont,Francesco Crea,Yan Ting Chiang,Dong Lin,Amy Zhang,James Z. L. Wang,Abhijit Parolia,Rebecca Wu,Hui Xue,Yuwei Wang,Jiarui Ding,Kelsie L. Thu,Wan L. Lam,Sohrab P. Shah,Colin C. Collins,Yuzhuo Wang,Cheryl D. Helgason
Clinical Epigenetics.2016;8(1)1203
[DOI]
25Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer
M. Pistelli,Z. Ballatore,A. Santinelli,T. Biscotti,F. Piva,G. Occhipinti,A. Della Mora,A. Pagliacci,N. Battelli,L. Bastianelli,M. De lisa,R. Bracci,E. Maccaroni,R. Berardi,S. Cascinu
Oncology Reports.2016;36(2)755
[DOI]
26VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
Zheren Shao,Qi Bao,Fangzhen Jiang,Huan Qian,Quan Fang,Xueqing Hu,Cong Cao
PLOS ONE.2015;10(7)e0132655
[DOI]
27The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence
David Schörghofer,Katharina Kinslechner,Andrea Preitschopf,Birgit Schütz,Clemens Röhrl,Markus Hengstschläger,Herbert Stangl,Mario Mikula
Reproductive Biology and Endocrinology.2015;13(1)e0132655
[DOI]
28Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgen-independent growth of prostate cancer cells
Huarong Huang,Yan He,Lanyue Zhang,Hongping Xiang,Dongli Li,Wenfeng Liu,Xue-Tao Xu,Susan Goodin,Kun Zhang,Xi Zheng
Food & Function.2018;9(4)2398
[DOI]
29Cross-talk between ribosome biogenesis, translation, and mTOR in CD133+?4/CD44+?prostate cancer stem cells
Z. Binal,E. Açikgöz,F. Kizilay,G. Öktem,B. Altay
Clinical and Translational Oncology.2020;22(7)1040
[DOI]
30Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway
Zhanyu Wang,Guojin Jia,Yan Li,Jikai Liu,Jinfang Luo,Jihong Zhang,Guoxiong Xu,Gang Chen
Oncotarget.2017;8(14)22563
[DOI]
31Novel Cancer Chemotherapy Hits by Molecular Topology: Dual Akt and Beta-Catenin Inhibitors
Riccardo Zanni,Maria Galvez-Llompart,Cecilia Morell,Nieves Rodríguez-Henche,Inés Díaz-Laviada,Maria Carmen Recio-Iglesias,Ramon Garcia-Domenech,Jorge Galvez,Yuan-Soon Ho
PLOS ONE.2015;10(4)e0124244
[DOI]
32Effect of Sulfated Polysaccharide from Undaria pinnatifida (SPUP) on Proliferation, Migration, and Apoptosis of Human Prostatic Cancer
Xiaolin Xu,Xin Zhu,Wenglong Lu,Yandong He,Yihan Wang,Feng Liu
International Journal of Polymer Science.2019;2019(4)1
[DOI]
33A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
Laura Graham,Kalyan Banda,Alba Torres,Brett S. Carver,Yu Chen,Katie Pisano,Greg Shelkey,Tracy Curley,Howard I. Scher,Tamara L. Lotan,Andrew C. Hsieh,Dana E. Rathkopf
Investigational New Drugs.2018;36(3)458
[DOI]
34PI3K/Akt signaling in osteosarcoma
Jian Zhang,Xiao-Hua Yu,Yi-Guo Yan,Cheng Wang,Wen-Jun Wang
Clinica Chimica Acta.2015;444(3)182
[DOI]
35The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models
Yun-Rong Zhu,Xiao-zhong Zhou,Lun-qing Zhu,Chen Yao,Jian-Feng Fang,Feng Zhou,Xiong-Wei Deng,Yun-Qing Zhang
Oncotarget.2016;7(31)49527
[DOI]
36Synergistic effects of phenylhexyl isothiocyanate and LY294002 on the PI3K/Akt signaling pathway in HL-60 cells
Huicong Yang,Yiqun Huang,Yong Zou,Xudong Ma
Oncology Letters.2017;14(3)3043
[DOI]
37Influence and mechanism of Angiotensin 1-7 on biological properties of normal prostate epithelial cells
Kamila Dominska,Piotr Okla,Karolina Kowalska,Dominika Ewa Habrowska-Górczynska,Kinga Anna Urbanek,Tomasz Ochedalski,Agnieszka Wanda Piastowska-Ciesielska
Biochemical and Biophysical Research Communications.2018;502(1)152
[DOI]
38MIIP inhibits the growth of prostate cancer via interaction with PP1a and negative modulation of AKT signaling
Guang Yan,Yi Ru,Fengqi Yan,Xin Xiong,Wei Hu,Tao Pan,Jianming Sun,Chi Zhang,Qinhao Wang,Xia Li
Cell Communication and Signaling.2019;17(1)152
[DOI]
39Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer
H. Alexander Ebhardt,Alex Root,Yansheng Liu,Nicholas Paul Gauthier,Chris Sander,Ruedi Aebersold
npj Systems Biology and Applications.2018;4(1)152
[DOI]
40PI3K pathway in prostate cancer: All resistant roads lead to PI3K
Soonbum Park,Young Sik Kim,Davis Yeon Kim,Insuk So,Ju-Hong Jeon
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2018;1870(2)198
[DOI]
41Long non-coding RNA CRNDE promote the progression of tongue squamous cell carcinoma through regulating the PI3K/AKT/mTOR signaling pathway
Zhongheng Yang,Weizhi Chen
RSC Advances.2019;9(37)21381
[DOI]
42

Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway

Bin Wang,Jingyu Li
Cancer Management and Research.2020;Volume 12(37)2631
[DOI]
43Dual PI3?K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling
Andrea Mancini,Alessandro Colapietro,Simona Pompili,Andrea Del Fattore,Simona Delle Monache,Leda Assunta Biordi,Adriano Angelucci,Vincenzo Mattei,Chris Liang,Giovanni Luca Gravina,Claudio Festuccia
Tumor Biology.2018;40(4)101042831877177
[DOI]
44Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets
Fabrizio Fontana,Michela Raimondi,Monica Marzagalli,Alessandro Di Domizio,Patrizia Limonta
Cells.2020;9(2)460
[DOI]
45PTEN loss and activation of K-RAS and ß-catenin cooperate to accelerate prostate tumourigenesis
Matthew T Jefferies,Adam C Cox,Boris Y Shorning,Valerie Meniel,David Griffiths,Howard G Kynaston,Matthew J Smalley,Alan R Clarke
The Journal of Pathology.2017;243(4)442
[DOI]
46A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer
Nisha R. Dahiya,Balaji Chandrasekaran,Venkatesh Kolluru,Murali Ankem,Chendil Damodaran,Manicka V. Vadhanam
Molecular Carcinogenesis.2018;57(10)1332
[DOI]
47Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro
Jasmina Makarevic,Igor Tsaur,Eva Juengel,Hendrik Borgmann,Karen Nelson,Christian Thomas,Georg Bartsch,Axel Haferkamp,Roman A. Blaheta
Life Sciences.2016;147(10)137
[DOI]
48MiR-1271 Inhibits Cell Growth in Prostate Cancer by Targeting ERG
Miao Wang,Wei Gao,Dehong Lu,Lianghong Teng
Pathology & Oncology Research.2018;24(2)385
[DOI]
49ABT-737 and erufosine combination against castration-resistant prostate cancer
Ezgi Avsar Abdik,Ferda Kaleagasioglu,Hüseyin Abdik,Fikrettin Sahin,Martin R. Berger
Anti-Cancer Drugs.2019;30(4)383
[DOI]
50Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism
Jing-Wen Shih,Ling-Yu Wang,Chiu-Lien Hung,Hsing-Jien Kung,Chia-Ling Hsieh
International Journal of Molecular Sciences.2015;16(12)28943
[DOI]
51RETRACTED: CircLMTK2 acts as a tumor suppressor in prostate cancer via regulating the expression of microRNA-183
Chengjun Jin,Weiming Zhao,Zijian Zhang,Wanpeng Liu
Life Sciences.2020;241(12)117097
[DOI]
52The Secret Life of Translation Initiation in Prostate Cancer
Greco Hernández,Jorge L. Ramírez,Abraham Pedroza-Torres,Luis A. Herrera,Miguel A. Jiménez-Ríos
Frontiers in Genetics.2019;10(12)117097
[DOI]
53Dairy Products: Is There an Impact on Promotion of Prostate Cancer? A Review of the Literature
Alexandra Vasconcelos,Teresa Santos,Paula Ravasco,Pedro Miguel Neves
Frontiers in Nutrition.2019;6(12)117097
[DOI]
54MiR-93 functions as a tumor promoter in prostate cancer by targeting disabled homolog 2 (DAB2) and an antitumor polysaccharide from green tea (Camellia sinensis) on their expression
Ke Yang,Yuan-Wei Li,Zhi-Yong Gao,Wei Xiao,Tie-Qiu Li,Wei Song,Jue Zheng,Hao Chen,Gui-Heng Chen,Hao-Yu Zou
International Journal of Biological Macromolecules.2019;125(12)557
[DOI]
55An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells
Zhizhuo Zhang,Kern Rei Chng,Shreyas Lingadahalli,Zikai Chen,Mei Hui Liu,Huy Hoang Do,Shaojiang Cai,Nicola Rinaldi,Huay Mei Poh,Guoliang Li,Ying Ying Sung,Charlie L. Heng,Leighton J. Core,Si Kee Tan,Xiaoan Ruan,John T. Lis,Manolis Kellis,Yijun Ruan,Wing-Kin Sung,Edwin Cheung
Genome Research.2019;29(2)223
[DOI]
56Transcription factor and microRNA-regulated network motifs for cancer and signal transduction networks
Wen-Tsong Hsieh,Ke-Rung Tzeng,Jin-Shuei Ciou,Jeffrey JP Tsai,Nilubon Kurubanjerdjit,Chien-Hung Huang,Ka-Lok Ng
BMC Systems Biology.2015;9(Suppl 1)S5
[DOI]
57CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel
Marjan Aghajani,Ahad Mokhtarzadeh,Leili Aghebati-Maleki,Behzad Mansoori,Ali Mohammadi,Sahar Safaei,Zahra Asadzadeh,Khalil Hajiasgharzadeh,Vahid Khaze Shahgoli,Behzad Baradaran
Molecular Biology Reports.2020;47(5)3691
[DOI]
58Milk—A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation
Bodo Melnik
International Journal of Molecular Sciences.2015;16(8)17048
[DOI]
59Effects of Brassicaceae Isothiocyanates on Prostate Cancer
Silvia Novío,María Cartea,Pilar Soengas,Manuel Freire-Garabal,María Núñez-Iglesias
Molecules.2016;21(5)626
[DOI]
60Hierarchical Micro-Nano Topography Promotes Cell Adhesion and Osteogenic Differentiation via Integrin a2-PI3K-AKT Signaling Axis
Huimin Zheng,Yujuan Tian,Qian Gao,Yingjie Yu,Xianyou Xia,Zhipeng Feng,Feng Dong,Xudong Wu,Lei Sui
Frontiers in Bioengineering and Biotechnology.2020;8(5)626
[DOI]
61Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo
Shang-jun Jiang,Shuo Wang
Tumor Biology.2015;36(10)8177
[DOI]
62Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3ß in a hamster model of oral oncogenesis
Josephraj Sophia,Kranthi Kiran Kishore T.,Jaganathan Kowshik,Rajakishore Mishra,Siddavaram Nagini
Scientific Reports.2016;6(1)8177
[DOI]
63Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats
Bianca Facchim Gonçalves,Silvana Gisele Pegorin de Campos,Wagner José Fávaro,Joyce Zalotti Brandt,Cristiane Figueiredo Pinho,Luis Antônio Justulin,Sebastião Roberto Taboga,Wellerson Rodrigo Scarano
Hormones and Cancer.2018;9(3)175
[DOI]
64T-cell lymphomas associated gene expression signature: Bioinformatics analysis based on gene expression Omnibus
Lei-lei Zhou,Xiao-yue Xu,Jie Ni,Xia Zhao,Jian-wei Zhou,Ji-feng Feng
European Journal of Haematology.2018;100(6)575
[DOI]
65Gene Expression Studies to Identify Significant Genes in AR, MTOR, MAPK Pathways and their Overlapping Regulatory Role in Prostate Cancer
Nimisha Asati,Abhinav Mishra,Ankita Shukla,Tiratha Raj Singh
Journal of Integrative Bioinformatics.2019;16(3)575
[DOI]
66Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation
He Wenjing,Yuanyuan Shao,Yi Yu,Wei Huang,Guoliang Feng,Junhe Li
The Prostate.2020;80(5)367
[DOI]
67Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation
Jason Boyang Wu,Leland W.K. Chung
The Prostate.2016;80(5)263
[DOI]
68Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Patricia Mucci LoRusso
Journal of Clinical Oncology.2016;34(31)3803
[DOI]
69mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Cara M. Statz,Sara E. Patterson,Susan M. Mockus
Targeted Oncology.2017;12(1)47
[DOI]
70Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy
Fan Xu,Yujing Gao,Yanqing Wang,Jiahua Pan,Jianjun Sha,Xiaoguang Shao,Xunlei Kang,Jun Qin,M. James You,Yiran Huang,Baijun Dong,Wei Xue
Oncotarget.2016;7(39)63294
[DOI]
71Mechanisms of Therapeutic Resistance in Prostate Cancer
Mary Nakazawa,Channing Paller,Natasha Kyprianou
Current Oncology Reports.2017;19(2)63294
[DOI]
72RNA-binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression
Jing Zhao,Yu Zhang,Xi-sheng Liu,Fang-ming Zhu,Feng Xie,Chen-yi Jiang,Zi-ye Zhang,Ying-li Gao,Yong-chuan Wang,Bin Li,Shu-jie Xia,Bang-min Han
Cancer Science.2020;111(2)369
[DOI]
73ACSL4 promotes prostate cancer growth, invasion and hormonal resistance
Xinyu Wu,Fangming Deng,Yirong Li,Garrett Daniels,Xinxin Du,Qinghu Ren,Jinhua Wang,Ling Hang Wang,Yang Yang,Valerio Zhang,David Zhang,Fei Ye,Jonathan Melamed,Marie E. Monaco,Peng Lee
Oncotarget.2015;6(42)44849
[DOI]
74Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients
S. Sideris,F. Aoun,C. N. Martinez,S. Latifyan,A. Awada,G. Costante,T. Gil
Journal of Endocrinological Investigation.2016;39(7)729
[DOI]
75PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence
Arunaksharan Narayanankutty
Current Drug Targets.2019;20(12)1217
[DOI]
76Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway
Yuxi Tian,Liangfang Shen,Fujun Li,Junwen Yang,Xiaoping Wan,Miao Ouyang
Journal of Cellular Physiology.2020;235(1)442
[DOI]
77AR Signaling and the PI3K Pathway in Prostate Cancer
Megan Crumbaker,Leila Khoja,Anthony Joshua
Cancers.2017;9(12)34
[DOI]
78Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
Giovanni Luca Gravina,Andrea Mancini,Alessandro Colapietro,Francesco Marampon,Roberta Sferra,Simona Pompili,Leda Assunta Biordi,Roberto Iorio,Vincenzo Flati,Christian Argueta,Yosef Landesman,Michael Kauffman,Sharon Shacham,Claudio Festuccia
Oncotarget.2017;8(67)111225
[DOI]
79MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer
Song Xu,Jingping Ge,Zhengyu Zhang,Wenquan Zhou
Biomedicine & Pharmacotherapy.2017;96(67)634
[DOI]
80MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer
Liang-Jun Yan,Zhiyou Cai
Biomedicine & Pharmacotherapy.2016;96(67)365
[DOI]
81Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer
Teng Ma,Hua Chen,Peilong Wang,Ningqiang Yang,Junsheng Bao
Cancer Biotherapy and Radiopharmaceuticals.2020;96(67)365
[DOI]
82Clinical implications of PTEN loss in prostate cancer
Tamara Jamaspishvili,David M. Berman,Ashley E. Ross,Howard I. Scher,Angelo M. De Marzo,Jeremy A. Squire,Tamara L. Lotan
Nature Reviews Urology.2018;15(4)222
[DOI]
83Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC-MS/MS
Sandeep R. Kunati,Yan Xu
Biomedical Chromatography.2017;31(3)e3818
[DOI]
84Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway
Fangzhen Cai,Yanmei Zhang,Jianwei Li,Sihuai Huang,Ruilin Gao
Bioscience Reports.2020;40(3)e3818
[DOI]
85A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
Xiao X. Wei,Andrew C. Hsieh,Won Kim,Terence Friedlander,Amy M. Lin,Mirela Louttit,Charles J. Ryan
The Oncologist.2017;22(5)503
[DOI]
86Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer
Wei Fu,Zhiming Hong,Xujun You,Jing Din,Baishu Chen,Beibei Zhao,Gengyan Yuan,Qixin Li
Biomedicine & Pharmacotherapy.2019;118(5)109374
[DOI]
87PIP5K1  inhibition as a therapeutic strategy for prostate cancer
J. M. Drake,J. Huang
Proceedings of the National Academy of Sciences.2014;111(35)12578
[DOI]
88mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma
Suzan Stelloo,Joyce Sanders,Ekaterina Nevedomskaya,Jeroen de Jong,Dennis Peters,Geert J.L.H. van Leenders,Guido Jenster,Andries M. Bergman,Wilbert Zwart
Oncotarget.2016;7(22)32916
[DOI]
89mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma
Simone de Brot,Nigel P. Mongan
Oncotarget.2018;7(22)381
[DOI]
90mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia
Fabio Di Domenico,Antonella Tramutola,Cesira Foppoli,Elizabeth Head,Marzia Perluigi,D. Allan Butterfield
Free Radical Biology and Medicine.2018;114(22)94
[DOI]
91Interaction between 3-Bromopyruvate and SC-514 in prostate cancer treatment
Toluleke Oloruntobi Famuyiwa,Joubin Jebelli,James Kwasi Kumi Diaka,Waseem Asghar
Journal of Cancer Prevention & Current Research.2018;9(6)94
[DOI]
92IL-8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF-?B pathway in prostate cancer
Yidi Guo,Ying Zang,Lianzheng Lv,Feng Cai,Tingting Qian,Guoying Zhang,Quancheng Feng
Molecular Medicine Reports.2017;16(6)9035
[DOI]
93Cell type–specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors
Andrew C. Hsieh,Hao G. Nguyen,Lexiaochuan Wen,Merritt P. Edlind,Peter R. Carroll,Won Kim,Davide Ruggero
Science Signaling.2015;8(403)ra116
[DOI]
94Acne vulgaris: The metabolic syndrome of the pilosebaceous follicle
Bodo C. Melnik
Clinics in Dermatology.2018;36(1)29
[DOI]
95DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals
Xiaoyu Chen,Xiufang Xiong,Danrui Cui,Fei Yang,Dongping Wei,Haomin Li,Jianfeng Shu,Yanli Bi,Xiaoqing Dai,Longyuan Gong,Yi Sun,Yongchao Zhao
Oncogene.2020;39(7)1557
[DOI]
96SNX-2112, an Hsp90 inhibitor, suppresses cervical cancer cells proliferation, migration, and invasion by inhibiting the Akt/mTOR signaling pathway
Liang-Shun Fu,Hong-Hong Qiu,Min Liu,Liu-Bing Hu,Yan Wang,Peng-Chao Zhang,Man-Mei Li,Yi-Fei Wang,Zhong Liu
Medicinal Chemistry Research.2020;29(6)942
[DOI]
97Protein kinase B
Bhumika Wadhwa,Ubaid Makhdoomi,Ram Vishwakarma,Fayaz Malik
Anti-Cancer Drugs.2017;28(6)569
[DOI]
98Protein kinase B
Takeo Kosaka,Mototsugu Oya
Anti-Cancer Drugs.2018;28(6)375
[DOI]
99A Systems-Level Analysis of Mechanisms of Platycodon grandiflorum Based on A Network Pharmacological Approach
Musun Park,Sa-Yoon Park,Hae-Jeung Lee,Chang-Eop Kim
Molecules.2018;23(11)2841
[DOI]
100pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks
Ege Ulgen,Ozan Ozisik,Osman Ugur Sezerman
Frontiers in Genetics.2019;10(11)2841
[DOI]
101MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity
Yang Wang,Ning Shao,Xueying Mao,Minmin Zhu,Weifei Fan,Zhixiang Shen,Rong Xiao,Chuncai Wang,Wenping Bao,Xinyu Xu,Chun Yang,Jian Dong,Deshui Yu,Yan Wu,Caixia Zhu,Liting Wen,Xiaojie Lu,Yong-Jie Lu,Ninghan Feng
Oncotarget.2016;7(30)47444
[DOI]
102Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways
Ewelina Górowska-Wójtowicz,Anna Hejmej,Alicja Kaminska,Laura Pardyak,Malgorzata Kotula-Balak,Joanna Dulinska-Litewka,Piotr Laidler,Barbara Bilinska
Toxicology in Vitro.2017;40(30)324
[DOI]
103Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
Toshihiko Doi,Yutaka Fujiwara,Nobuaki Matsubara,Junichi Tomomatsu,Satoru Iwasa,Akari Tanaka,Chihiro Endo-Tsukude,Shintaro Nakagawa,Shunji Takahashi
Cancer Chemotherapy and Pharmacology.2019;84(2)393
[DOI]
104Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
Zhonglin Cai,Weijie Chen,Jianzhong Zhang,Hongjun Li
International Urology and Nephrology.2018;50(10)1753
[DOI]
105Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression
Xuechao Wan,Wenhua Huang,Shu Yang,Yalong Zhang,Pu Zhang,Zhe Kong,Tao Li,Hai Wu,Fengxiang Jing,Yao Li
The International Journal of Biochemistry & Cell Biology.2016;79(10)249
[DOI]
Feedback

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal